Form 4: Regeneron Director Bonnie L. Bassler Acquires Stock and Options

Director Bonnie L. Bassler reports acquisition of Regeneron stock and options.

Summary

• On January 2, 2025, Bonnie L. Bassler, a director of Regeneron Pharmaceuticals, acquired 166 shares of common stock and 1,958 non-qualified stock options.
• The stock was acquired at a price of $0.0, and the exercise price for the options is $719.37.
• Following these transactions, Bassler directly owns 1,548 shares of Regeneron common stock and 1,958 derivative securities.
• The options become exercisable in portions, starting on the date of the Issuer's first annual meeting of shareholders following the date of grant, and the remainder on the first anniversary of the date of grant, expiring on January 2, 2035.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard disclosure of stock and option acquisitions by a company director.

Positives

• The acquisition of stock and options by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders. This filing indicates changes in beneficial ownership for a Regeneron director.

Stakeholder Impact

• The acquisition of shares and options by a director can influence investor sentiment.

Key Dates